17 jul: Parken: FCK forhandler med flere om N'Doye-salg
18 jul: OPTAKT Nordea Q2 18/7: Drift holdt nede af nedskrivninger
17-07-2012 23:37:00

GlaxoSmithKline and Amicus Expand Drug Collaboration

Relateret indhold

By Ben Fox Rubin

Amicus Therapeutics Inc. (FOLD) and GlaxoSmithKline PLC (GSK, GSK.LN) said they are expanding their collaboration to develop a treatment for Fabry disease, with Glaxo agreeing to buy a larger stake in the smaller pharmaceutical company.

The deal includes co-development of all current and future formulations of migalastat HCl for Fabry disease, which is a lipid storage disorder, as well as a commercialization arrangement for all future Fabry products. Amicus will have commercial rights in the U.S., while Glaxo will have rights for the rest of the world.

Glaxo also agreed to buy $18.6 million in Amicus's common stock at $6.30 a share, a 4.7% premium over Tuesday's close, raising its ownership in the company to 20%.

"Through our expanded agreement, GSK is increasing its investment in the Fabry development program and Amicus is transforming into a commercial-stage biopharmaceutical company within the U.S.," said Amicus Chief Executive John Crowley.

Amicus makes oral therapeutics known as pharmacological chaperones to treat a range of human genetic diseases.

Its shares closed Tuesday at $6.02, while Glaxo's closed at $45.44. Neither were active after hours.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 17, 2012 17:37 ET (21:37 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Rockwool/Jyske: Ledelsen gør klar til at fokusere på vækst igen

26-08-2016 15:15:02
Det spareprogram, som Rockwools topchef, Jens Birgersson, igangsatte sidste år, begynder så småt at nærme sig en afslutning. Og dermed kan stenuldsproducentens ..

Simcorp/CEO: Abonnementsmodel bag rekordstor ordrebog

26-08-2016 13:14:42
Softwareselskabet Simcorp kunne ved udgangen af første halvår notere sig den fedeste ordrebog i selskabets historie.Det er der en god forklaring på, lyder det f..

Aktier/middag: Genmab og Novo trækker ned inden nyt fra Yellen

26-08-2016 11:41:55
Kursfald i blandt andre Novo Nordisk og Genmab medvirker til at sætte det danske aktiemarked en smule under pres fredag middag.Markedet holder vejret op til eft..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Glaxosmithkline PLC ORD .. 1.648,13 -0,3% Fald i aktiekurs
GlaxoSmithKline PLC 43,55 -0,4% Fald i aktiekurs
Amicus Therapeutics Inc 6,98 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. august 2016 22:28:47
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160826.1 - EUROWEB2 - 2016-08-27 22:28:47 - 2016-08-27 22:28:47 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x